We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$414M
AUM Growth
-$24.8M
Cap. Flow
+$88.7M
Cap. Flow %
21.41%
Top 10 Hldgs %
52.02%
Holding
86
New
35
Increased
13
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$19.1M
2
SNY icon
Sanofi
SNY
+$18.3M
3
LH icon
Labcorp
LH
+$13.4M
4
COR icon
Cencora
COR
+$11.5M
5
CRL icon
Charles River Laboratories
CRL
+$7.22M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$19.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$12.5M
3
ICLR icon
Icon
ICLR
+$12.2M
4
JNJ icon
Johnson & Johnson
JNJ
+$9.06M
5
ACH
Accendra Health
ACH
+$7.11M

Sector Composition

Rank Sector Weight
1 Healthcare 72.05%
2 Industrials 1.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$29M 7%
60,900
+35,600
+141% +$16.3M
SNY icon
2
Sanofi
SNY
$103B
$21.3M 5.13%
424,490
+369,669
+674% +$18.3M
LH icon
3
Labcorp
LH
$25B
$20.5M 4.96%
76,093
+54,176
+247% +$13.4M
AZN icon
4
AstraZeneca
AZN
$263B
$18.9M 4.57%
+162,364
New +$19.1M
SIBN icon
5
SI-BONE Inc
SIBN
$788M
$17M 4.11%
767,126
+295,912
+63% +$6.37M
HUM icon
6
Humana
HUM
$43.7B
$15.8M 3.8%
33,981
-10,041
-23% -$4.44M
COR icon
7
Cencora
COR
$60.6B
$15.3M 3.69%
115,003
+93,573
+437% +$11.5M
HOLX
8
DELISTED
Hologic
HOLX
$13.9M 3.35%
181,068
-19,051
-10% -$1.4M
XBI icon
9
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$12.8M 3.09%
+114,300
New +$13.8M
THC icon
10
Tenet Healthcare
THC
$20.5B
$12M 2.9%
146,929
-32,359
-18% -$2.36M
BIO icon
11
Bio-Rad Laboratories Class A
BIO
$8.71B
$11M 2.65%
14,539
-3,733
-20% -$2.79M
XRAY icon
12
Dentsply Sirona
XRAY
$2.68B
$9.62M 2.32%
172,384
+111,764
+184% +$6.15M
BDX icon
13
Becton Dickinson
BDX
$45.6B
$8.66M 2.09%
35,313
+23,959
+211% +$5.74M
CI icon
14
Cigna
CI
$73.7B
$8.41M 2.03%
36,646
+458
+1% +$97.3K
SYNH
15
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$7.73M 1.87%
75,275
-17,486
-19% -$1.68M
JNJ icon
16
Johnson & Johnson
JNJ
$618B
$7.32M 1.77%
42,762
-55,315
-56% -$9.06M
CRL icon
17
Charles River Laboratories
CRL
$11.2B
$7M 1.69%
+18,586
New +$7.22M
RNAC icon
18
Cartesian Therapeutics
RNAC
$229M
$6.92M 1.67%
70,784
+36,734
+108% +$3.95M
ELUT icon
19
Elutia
ELUT
$37.9M
$6.78M 1.64%
1,075,640
+123,030
+13% +$721K
RVTY icon
20
Revvity
RVTY
$12.6B
$5.94M 1.43%
29,543
+10,279
+53% +$1.86M
CNC icon
21
Centene
CNC
$30.7B
$5.83M 1.41%
+70,809
New +$5.19M
XBI icon
22
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$5.48M 1.32%
+48,906
New +$5.9M
OCDX
23
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$5.25M 1.27%
+245,484
New +$4.84M
RCM
24
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.24M 1.26%
205,400
-77,511
-27% -$1.86M
OCUL icon
25
Ocular Therapeutix
OCUL
$1.79B
$5M 1.21%
717,143
+106,742
+17% +$829K
1
2 3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Endurant Capital Management held 86 positions worth $414M, down 5.7% from $439M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Endurant Capital Management deployed $88.7M of net new capital in Q4 2021, opening 35 new positions and adding to 13 existing holdings. Its largest new stake was AstraZeneca: 162,364 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 60% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Johnson & Johnson, an estimated $9.06M trimmed.

  • Endurant Capital Management's largest Q4 2021 buy was AstraZeneca: 162,364 shares worth $18.9M.
  • Endurant Capital Management added most to Sanofi in Q4 2021, an estimated $18.3M increase.
  • Endurant Capital Management's biggest Q4 2021 reduction was Johnson & Johnson, cutting an estimated $9.06M.
  • Endurant Capital Management fully exited AbbVie in Q4 2021, selling an estimated $19.5M.
  • Endurant Capital Management's ten largest holdings make up 52% of its $414M portfolio in Q4 2021.
  • Endurant Capital Management opened 35 new positions and closed 18 in Q4 2021.
  • Endurant Capital Management's portfolio value fell 5.7% quarter-over-quarter to $414M.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.